XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

This is a single-center, open label, single-arm, investigator-initiated study to evaluate the efficacy and safety of XH001 (neoantigen cancer vaccine) sequential combination with immunocheckpoint inhibitor and chemotherapy in pancreatic cancer patients following surgical resection.

Trial Details

NCT ID
NCT06353646
Phase
NA
Sponsor
Wu Wenming
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • XH001
  • Ipilimumab Injection
  • Sintilimab injection
  • Chemotherapy
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Provision of signed and dated informed consent form;
  • Aged 18 to 75 years old;
  • Histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma;
  • Completed an R0 or R1 surgical resection as determined by pathology；

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →